Investigation for clinical efficacy and safety of ipragliflozin 50mg and 100mg on type 2 diabetes - HARUKA study

Osaka Saiseikai Nakatsu Hospital Division of diabetes and endocrinology0 sites600 target enrollmentJanuary 6, 2015

Overview

Phase: N/A
Intervention: Not specified
Conditions: Type 2 diabetes
Sponsor: Osaka Saiseikai Nakatsu Hospital Division of diabetes and endocrinology
Enrollment: 600
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

January 6, 2015

End Date

September 30, 2017

Last Updated

2 years ago

Study Type

Observational

Sex

All

Sponsor

Osaka Saiseikai Nakatsu Hospital Division of diabetes and endocrinology

•1\) Type 1 diabetes, patients with other types of diabetes or pregnancy diabetes 2\) History of severe ketoacidosis diabetic coma or profound come within 6 months 3\) Severe infection, perioperative or severe trauma 4\) Moderate renal insufficiency(male \>1\.5mg/dL, female\>1\.3mg/dL) 5\) Severe hepatic impairment 6\) History of requirement of hospitalization for severe CV event within 6 months other 7\) Patients with pregnancy, breast\-feeding, childbearing potential or plan of pregnancy 8\) Patients with neuropathic bladder or dysuria 9\) Patients with treatment of diuretic drug 10\) Patients with SGLT2 treatment at start of this study 11\) Patients who has an episode of sensitivity of SGLT\-2 12\) Patients who are not eligible judged by investigator